The Independent Data Monitoring Committee overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the ...

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after ...

Praxis Precision Medicines (NASDAQ:PRAX) announced Friday that the company will advance its Essential3 program for its lead asset ulixacaltamide against the neurological disorder essential tremor, ...

Praxis on Friday said the independent data monitoring committee overseeing an interim analysis of Study 1 of the "Essential3" program has recommended that the study be stopped for futility because it ...

After Study 1’s independent data monitoring committee said the experiment will likely fall short of its primary endpoint with ulixacaltamide in essential tremor, Praxis Precision Medicines Inc. plans ...

REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Tr ...